PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
-9.66%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$1.21B
AUM Growth
+$1.21B
(-30%)
Cap. Flow
-$387M
Cap. Flow
% of AUM
-31.95%
Top 10 Holdings %
Top 10 Hldgs %
37.67%
Holding
84
New
25
Increased
14
Reduced
19
Closed
21
Top Buys
| 1 |
McKesson
MCK
|
$46.5M |
| 2 |
AbbVie
ABBV
|
$42.5M |
| 3 |
Cardinal Health
CAH
|
$42.1M |
| 4 |
Becton Dickinson
BDX
|
$34.7M |
| 5 |
Cencora
COR
|
$30M |
Top Sells
| 1 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$73.8M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
$67.8M |
| 3 |
Zimmer Biomet
ZBH
|
$66.3M |
| 4 |
Gilead Sciences
GILD
|
$59.7M |
| 5 |
AGN
Allergan plc
AGN
|
$53.8M |
Sector Composition
| 1 | Healthcare | 84.85% |
| 2 | Technology | 3.15% |
| 3 | Consumer Discretionary | 1.98% |
| 4 | Industrials | 0.46% |
| 5 | Utilities | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $61.6M | 5.06% | 686,249 -390,193 | -36% | -$35M |
|
|
2
AbbVie
ABBV
$372B
| $55.2M | 4.53% | 724,174 +557,935 | +336% | +$42.5M |
|
3
Elevance Health
ELV
$71.8B
| $50.8M | 4.18% | 223,925 +25,377 | +13% | +$5.76M |
|
|
4
McKesson
MCK
$85.4B
| $46.5M | 3.82% | +343,950 | New | +$46.5M |
|
|
5
Cardinal Health
CAH
$35.5B
| $42.1M | 3.46% | +878,531 | New | +$42.1M |
|
|
6
Gilead Sciences
GILD
$140B
| $41.4M | 3.4% | 553,339 -798,397 | -59% | -$59.7M |
|
7
ICU Medical
ICUI
$3.15B
| $40.8M | 3.35% | 202,339 +36,674 | +22% | +$7.4M |
|
8
Pfizer
PFE
$141B
| $38.5M | 3.17% | 1,180,658 +257,532 | +28% | +$8.41M |
|
|
KRTX
9
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $36M | 2.95% | 499,510 -103,041 | -17% | -$7.42M |
|
|
10
Becton Dickinson
BDX
$55.3B
| $34.7M | 2.85% | +151,150 | New | +$34.7M |
|
11
Cigna
CI
$80.3B
| $34.5M | 2.83% | 194,690 -71,027 | -27% | -$12.6M |
|
|
AERI
12
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $34.1M | 2.8% | 2,528,276 +114,812 | +5% | +$1.55M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $33.8M | 2.77% | 399,605 -154,029 | -28% | -$13M |
|
14
Humana
HUM
$36.5B
| $32.4M | 2.66% | 103,030 +23,484 | +30% | +$7.37M |
|
|
ARNA
15
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $31.5M | 2.58% | 749,217 -321,399 | -30% | -$13.5M |
|
|
16
Cencora
COR
$56.5B
| $30M | 2.46% | +338,732 | New | +$30M |
|
17
Heron Therapeutics
HRTX
$207M
| $29.1M | 2.39% | +2,481,917 | New | +$29.1M |
|
18
UnitedHealth
UNH
$281B
| $26.1M | 2.14% | 104,722 +10,023 | +11% | +$2.5M |
|
19
Biogen
BIIB
$19.4B
| $25.6M | 2.11% | 81,013 -147,315 | -65% | -$46.6M |
|
20
Baxter International
BAX
$12.7B
| $25.1M | 2.06% | +309,635 | New | +$25.1M |
|
21
Vertex Pharmaceuticals
VRTX
$100B
| $22.7M | 1.87% | 95,482 +38,560 | +68% | +$9.18M |
|
22
Edwards Lifesciences
EW
$47.8B
| $22.3M | 1.83% | 118,392 +15,113 | +15% | +$2.85M |
|
23
Johnson & Johnson
JNJ
$427B
| $21.8M | 1.79% | +166,375 | New | +$21.8M |
|
24
Penumbra
PEN
$10.6B
| $19.1M | 1.57% | 118,190 -300,602 | -72% | -$48.5M |
|
25
iRhythm Technologies
IRTC
$5.46B
| $19M | 1.56% | 233,409 -224,832 | -49% | -$18.3M |
|